Project Updates
Upsher-Smiths, US
Plant C has fully updated serialisation and packaging capabilities and supports contract manufacturing. Credit: Upsher-Smith Laboratories, LLC.
Project name: Upsher-Smiths Pharmaceutical Manufacturing Facility, US
Location: Maple Grove, Minnesota
Project type: Pharmaceutical manufacturing facility
Investment: $100m
Upsher-Smith Laboratories has opened a new facility known as Plant C. The facility has increased the capacity for packaging, distribution, logistics, and warehousing of the company’s products, which include more than 150 branded and generic products.
Kite Pharma, US
Kite Pharma’s Viral Vector Manufacturing Facility in Oceanside, California. Credit: Kite Pharma
Project name: Kite Pharma’s Viral Vector Manufacturing Facility
Location: Oceanside, California, US
Project type: Viral vector manufacturing facility
Approved for Commercial Production: October 2022
Gilead Sciences subsidiary Kite Pharma’ facility is being used for manufacturing viral vectors to produce cell therapy, as well as the company’s chimeric antigen receptor T (CAR T) cell therapy Yescarta.
Evonik Pharmaceuticals, Germany
Evonik's GMP facility at its Hanau site. Credit: Evonik.
Project name: Evonik’s Pharmaceutical Lipids Manufacturing Facility
Location: Hanau, Germany
Project type: Pharmaceutical lipids manufacturing facility
Opened: March 2023
Evonik opened a new GMP facility to manufacture pharmaceutical lipids for clinical development and small-scale commercialisation at its existing site in Hanau.
